OSI 027

Drug Profile

OSI 027

Alternative Names: OSI-027

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator OSI Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Antineoplastics; Carboxylic acids; Imidazoles; Indoles; Pyrazines; Small molecules; Triazines
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Lymphoma; Solid tumours
  • Discontinued Renal cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease) in Belgium (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease) in United Kingdom (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top